NCT00162305 - A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

BMS-512148

Capsules, Oral, 100 mg, Once daily, 14 days.

DRUG

BMS-512148

Capsules, Oral, 25 mg, Once daily, 14 days.

DRUG

BMS-512148

Capsules, Oral, 5 mg, Once daily, 14 days.

DRUG

Placebo

Capsules, Oral, 0 mg, Once daily, 14 days.

Trial Locations (5)

Local Institution, Orlando

Local Institution, Miami

Local Institution, Fort Lauderdale

Local Institution, New Orleans

Local Institution, San Antonio